DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF ENALAPRIL MALEATE IN PRESENT OF THEIR IMPURITIES: APPLICATION TO TABLET ANALYSIS by Logoyda, Liliya et al.
 
 
DEVELOPMENT AND VALIDATION OF HPLC METHOD FOR THE SIMULTANEOUS 
DETERMINATION OF ENALAPRIL MALEATE IN PRESENT OF THEIR IMPURITIES: 
APPLICATION TO TABLET ANALYSIS 
Original Article 
 
LILIYA LOGOYDA1*, AHMED M. ABDEL-MEGIED2, YULIYA KONDRATOVA3, OLENA TROFIMENKO3, DMYTRO 
KOROBKO1, IRYNA DAKHYM4 
1Pharmaceutical Chemistry Department, Pharmaceutical Faculty, I. Horbachevsky Ternopil State Medical University, Ternopil City, 
Ukraine, 2Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy and Pharmaceutical Manufacturing, Kafrelsheikh 
University, Kafrelsheikh City, Egypt, 3Central R and D Laboratory JSC Farmak, Kyiv City Ukraine, 4
Received: 27 Sep 2017, Revised and Accepted: 28 Nov 2017 
Pharmacognosy and Medical Botany 
Department, Pharmaceutical Faculty, I. Horbachevsky Ternopil State Medical University, Ternopil City, Ukraine 
Email: logojda@tdmu.edu.ua  
Objective: 
ABSTRACT 
A simple, rapid, economical, and highly sensitive stability-indicating HPLC method was developed and fully validated for determination 
of enalapril maleate in presence of its related substances namely enalaprilat dihydrate and diketopiperazine
Methods: Chromatographic separation was achieved on Grace Platinumр C8 EPS column (4.6 mm i.d. X 250 mm, 5 μm) at room temperature. The 
mobile phase consisted of acetonitrile: 20 mmol phosphate buffer adjusted to pH 2.2 (25:75 v/v) isocratically pumped at a flow rate 2 ml/min and 
UV-detection was monitored at 215 nm. 
. 
Results: The proposed method was validated according to ICH guidelines with total run time less than 9 min. The correlation coefficient (r2
Conclusion: A rapid, economical, simple and sensitive HPLC method was developed and validated for the determination of enalapril maleate in 
tablet dosage form in presence of their impurities. The developed method can help research studies, quality control and routine analysis with lesser 
resources available. Therefore, the proposed validated method is fast and reliable and can be used for routine quantitative analysis as well as 
quality control of enalapril maleate in pharmaceutical formulation. 
) was 
noted as 0.99981 which states that the method was good linear to the concentration versus peak area responses. The developed method found to be 
high sensitivity with LOD and LOQ of 0.021 and 0.062 %; respectively. The developed, validated method was successfully applied for the 
determination of enalapril maleate in presence of their impurities in tablet dosage form.  
Keywords: Enalapril maleate, Enalaprilat dihydrate, High-Performance Liquid Chromatography, Validation, ICH guidelines 




Enalapril maleate is chemically described as (2S)-1-[(2S)-2-[[(1S)-1-
(Ethoxycarbonyl)-3-phenylpropyl] amino] propanoyl] pyrrolidine-2-
carboxylic acid (Z)-butenedioate (fig. 1). Enalapril maleate is a prodrug 
which metabolized rapidly in the liver to ethyl ester of a long-acting 
enalaprilat which inhibits angiotensin-converting enzyme (ACE) in 
human subjects and animals. ACE is a peptidyl dipeptidase that 
catalyzes the conversion of angiotensin I to the vasoconstrictor 
substance, angiotensin II. Angiotensin II also stimulates aldosterone 
secretion by the adrenal cortex. The beneficial effects in hypertension 
and heart failure appear to result primarily from suppression of the 
renin-angiotensin-aldosterone system. Inhibition of ACE results in 
decreased plasma angiotensin II, which leads to decreased 
vasopressor activity and to decrease aldosterone secretion [1]. 
 
 
Fig. 1: Chemical structure of enalapril maleate 
 
A literature survey was conducted and several methods were reported 
for the determination of enalapril maleate including the following 
methods: UV-Visible spectrophotometry [2-4], HPLC [5-13], HPTLC 
[14] and LC-MS/MS [15-17]. Previous reported method showed long 
retention time for enalapril maleate (9.7 min). However, no rapid and 
sensitive HPLC for the determination of enalapril maleate in its tablet 
dosage form. It was necessity to develop a shorter run time assay 
method for the determination of enalapril maleate tablets which lead 
to decrease in coast of analysis and reliable method to be used in 
quality control laboratories. The HPLC method for determination of 
enalapril maleate and related substances is official in European 
Pharmacopoeia (EP) [18]. Meanwhile, the reported method suffers 
from some drawbacks such as column oven should be thermostated at 
70 °C lead to variation with different instruments. In addition, 
maximum limit of column oven temperature is 65 °C only for Waters 
and Shimadzu. On contrary, this novel proposed work represents a 
new HPLC method which is capable of separating all impurities with 
high resolution at room temperature getting more superior to the 
existing monograph methods. However, it was necessary to develop a 
simple, rapid, economical and sensitive HPLC for the determination of 
impurities in enalapril maleate in tablet dosage form. 
MATERIALS AND METHODS 
Chemicals and reagents 
Enalapril maleate, enalaprilat dihydrate, diketopiperazine were 
obtained as a gift from Farmak pharmaceuticals (Kiev, Ukraine). 
HPLC grade acetonitrile, sodium dihydrophosphate dihydrate, 
phosphoric acid were obtained from Merck pharamaceticals. 
Instrumentation and chromatographic conditions 
HPLC system equipped with Agilent 1260, Grace Platinumр C8 EPS 
column (4.6 mm i.d. X 250 mm, 5 μm). Chromatographic separation 
was carriеd out at ambient temperature (22 °C-25 °C). All analytes 
were separated isocratically with a mobile phasе consisting of 
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acetonitrile and phosphate buffer pH 2.2 (25/75, v/v), at a flow rate 
2.0 ml/min with injection volume 50 μL. The effluent was monitorеd 
spectrophotometrically at 215 nm.  
Preparation of mobile phase 
To prepare buffer solution pH 2.2.: 3.59 g of sodium dihydro-
phosphate dihydrate was dissolved in 1800 ml of water, was fixed 
the pH of the solution to the value (2.2±0.05) with phosphoric acid 
and then was added the volume of the solution with water R to 
2000.0 ml and was mixed. 
Stock standard solutions 
20 mg of the standard enalapril maleate was dissolved in mobile 
phase, was added 0.5 ml of enalaprilat
Once the chromatographic and the experimental conditions were 
established, the method was validated according to ICH Q2 (R1) 
guidelines [19]. 
 dihydrate with a 
concentration of 0.4 mg/ml and 2.0 ml of diketopiperazine at a 
concentration of 0.4 mg/ml then was adjusted to a volume of 100.0 
ml with the same solvent. 
Procedures  
The standard solutions were prepared by dilution of the stock 
standard solution with mobile phase. Triplicate 50.0 μL injections 
were made for each concentration and chromatographed under the 
condition described above. The peak area of each concentration was 
plotted against the corresponding concentration to obtain the 
calibration graph and regression equation was computed. 
Analysis of dosage form 
Accurately weighed twenty Enalozid® tablets and average weight was 
calculated. A powder equivalent to 10 mg of enalapril maleate was 
transfered into a 50 ml volumetric flask. 30 ml phosphate buffer 
solution (pH 2.2) was added and sonicated for 15 min. Solvent (buffer 
solution pH 2.2) was adjusted up to the mark. The solution was filtered 
using 0.45 μm nylon filter. The amount present in the tablet was 
calculated from plotted calibration graph or utilizing regression 
equation. After setting the chromatographic conditions and stabilizing 
the instrument to obtain a steady baseline, the sample solution was 
loaded in the 50 μl fixed sample loop of the injection port. The 
concentration of the solution is 0.2 mg/ml. The comparison solution 
for the calculation of impurities is prepared from the solution of the 
preparation, obtaining a concentration of 0.02 mg/ml. 
Method validation 
System suitability tests have been checked by injecting different 
concentrations of enalapril maleate and related substances working 
standard and separation factor was monitored throughout the 
validation process.  
Specificity of an analytical method is its ability to measure accurately 
and specifically the analyte of interest without interference from 
placebo and degradation products. The specificity of the method was 
established by injecting blank, placebo and standard solution in 
triplicate and recording the chromatograms. 
Linearity of the detector response was applied by preparing calibration 
sample solutions starting with LOQ concentration. Each set of solutions 
were prepared in triplicates and analyzed for three successive days. 
Sample concentration and areas were used by plot calibration curves, 
the % RSD and Y-intercept of the calibration curves were computed. 
Limit of detection is the lowest concentration in a sample that can be 
detected, but not necessarily quantified under the stated 
experimental conditions. The limit of quantitation is the lowest 
concentration of analyte in a sample which can be quantitatively 
determined with suitable precision and accuracy.  
LOD and LOQ were determined at a signal to noise ratio LOD= 3.3 
σ/S and LOQ = 10 σ/S, where σ is the standard deviation of 
intercept, S is the slope derived from calibration curve.  
RESULTS AND DISCUSSION 
Method development and optimization 
The proposed HPLC method was developed to provide specific 
procedure for the rapid quality control analysis [20, 21]. This 
method provides high sensitivity for determination of enalapril 
maleate in presence of their impurities. To find the appropriate 
HPLC conditions, various columns, isocratic and gradient mobile 
phase systems were tried, and successfully attempts were 
performed using Grace Platinumр C8 EPS column (4.6 mm i.d. X 250 
mm, 5 μm) and mobile phase consists of acetonitrile and phosphate 
buffer solution (pH 2.2) in the proportion (25/75, v/v), at a flow rate 
of 2.0 ml/min with UV detection at 215 nm. Typical chromatogram 
(fig. 2), which shows a clear separation between the peaks of API, 
admixtures and placebo. The optimum chromatographic conditions 
and system suitability parameters are tabulated in table 1. 
Previous reported method showed long retention time for enalapril 
maleate (9.7 min). Upon comparison with our present work; a 
shorter run time assay method was developed for the determination 
of enalapril maleate tablets which lead to decrease in cost of analysis 
and reliable method to be used in quality control laboratories. 
  
 
Fig. 2: Representative HPLC chromatogram of enalapril maleate (0.02 mg/ml) in presence of enalaprilat dehydrate and diketopiperazine 
using UV detection at 215 nm 
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Table 1: Optimized chromatographic conditions 
Parameter Chromatographic conditions 
Instrument Agilent 1260 
Column Grace Platinumр C8 EPS column (4.6 mm i.d. X 250 mm, 5 μm) 
Mobile phase acetonitrile and buffer solution pH 2.2 (25/75, v/v) 
Flow rate 2.0 ml/min 
Detection wavelength UV at 215 nm 
Runtime 10 min 
Column temperature 30 ° C 
Volume of injection loop 50 μl 
 
System suitability 
According to the requirements of the methods, the chromatographic 
system is considered suitable if such conditions are satisfied for the 
chromatographic results of the reference solution:  
 The actual absolute retention time of enalapril maleate peak 
should be about 4.4 min;  
 The actual relative retention time, with respect to enalapril 
maleate peak, should be about 0.5 for enalaprilat
According to validation data obtained for the reference solution, the 
parameters of the chromatographic system were:  
 dihydrate peak and 
about 1.9 for diketopiperazine. 
 The actual absolute retention time of enalapril maleate peak is 4.24 
min;  
 The actual relative retention time, with respect to enalapril 
maleate peak of about 2.37/4.24 = 0.56 for enalaprilat
Thus, the parameters of the chromatographic system required by both 




peak and about 8.11/4.24 = 1.91 for peak of diketopiperazine. 
Under the above described experimental conditions, the linearity of 
the proposed HPLC method was investigated by analyzing a series of 
different concentrations by plotting the peak area against the 
concentration of standard drugs. The results of chromatographic 
determination of model solutions are present in table 2. 
The calibration plot and characteristics of the linear dependence 
presented in (fig. 3 and table 3).  
 
 
Fig. 3: The calibration curve for enalozide mono tablets
 
Table 2: Chromatographic determination of model solutions of enalapril maleate and solution (Enalozid_RS_d_1%) 
Model solutions (Ci/Ctest) × 100 % Si  Average Sparallel measurements RSDi i, , % 
MS1 0.10 6.04 6.19 5.10 
5.98 
6.55 
MS2 0.20 10.57 10.43 3.25 
10.04 
10.66 
MS3 0.40 21.69 21.53 1.20 
21.23 
21.66 
MS4 0.60 32.19 32.05 0.39 
31.95 
32.02 
MS5 0.80 43.42 43.70 0.84 
43.56 
44.11 
MS6 1.00 54.24 54.07 0.73 
53.62 
54.35 
MS7 1.20 64.32 64.76 0.68 
64.75 
65.19 





*Average of 3 determinants, SD=Standard deviation, RSD=Relative standard deviation 
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Table 3: Characteristics of the linear dependence 
The name of the quantity Value 
B 53.86459 
s 0.46412 B 
A 0.1589 
s 0.33514 A 
s 0.466117 R 
sR 0.008654 /B 
R 0.99981 
 
The results obtained were procеssed by the least squares method. The 
correlation coefficient (r2
Specificity 
) was noted as 0.99981 which states that the 
method was good linear to the concentration versus peak area 
responses. The results show that a phenomenal relationship between 
peak area and concentration of the drug in the calibration curve. 
Results indicate high sensitivity of the proposed HPLC method.  
Commonly used tablet excipients did not interfere with the 
proposed method. It was shown that there is no interference 
between the peaks of the potential admixtures taken into account 
with each other and with the peak of the API (table 4)-i.e. 
  
Table 4: Specificity study 
Name of the solution Retention time (tR) min 
Mobile phase No peaks 
Placebo 










The technique is specific for any single impurities. The placebo 
solution as well as sample solution of enalapril maleate tablets 
was analyzed as per proposed method and it was found that 
there was no interference of excipients with the enalapril 
maleate peak.  
The peak purity of enalapril maleate peak was checked in the 
sample solution spiked with known related substances of 
enalaprilat
LOD and LOQ 
 dihydrate and diketopiperazine. Furthermore, the 
well shaped peaks also indicate the specificity of the method.  
LOD and LOQ were estimated a single to noise ratio of 3.3 σ/S and 
10 σ/S where σ is the standard deviation of intercept, S is the slope 
derived from calibration curve. 
Limit of detection (LOD) = 3.3 × sA
Limit of quantitation (LOQ)=10 × s
/B=3.3 × 0.33514/53.86459 = 0.021% 
A
The LOD and LOQ values are presented in table 5. 
/B=10 × 0.33514/53.86459=0.062% 
 
Table 5: LOD and LOQ of the proposed HPLC method for enalapril maleate 
Limit of Detection (LOD) 0.021 % 
Limit of Quantitation (LOQ) 0.062 % 
 
The developed method found to be high sensitivity with LOD and 
LOQ of 0.021 and 0.062 %; respectively. The results of LOD and LOQ 
supported the sensitivity of the proposed method. Summary of 
validation presents in table 6. The developed, validated method was 
successfully applied for the determination of enalapril maleate in 
presence of their impurities in tablet dosage form. 
 
Table 6: Summary of validation 
Validation 
characteristics 
Requirements Validation result Compliance 
Specificity Absence of interference of the peaks of the potential 
admixtures taken into account with each other and with 
the API peak  
Have showen absence of interference of the 
peaks of the potential admixtures taken into 




Limits of study ranges for any single impurity are defined 
as 0.10-1.20 % with respect to the nominal (200 μg/ml) 
concentration of enalapril maleate in the test solutions. 
It was studied in the indicated concentration 
limits for linearity, the limit of detection and the 
limit of quantitation 
Performed 
Linearity It should be confirmed by the least-squares statistical 
method in the range of API application:  
R ≥ 0,9950 
Confirmed statistically in the range of 
application:  
R = 0,9998 
Performed 
Limit of Detection 
(LOD) 
For any detectable single impurity:  
Not more than 32% of the limit of 0.1% 
Found: 0.021 %<0.32 × 0.1 = 0.032 % 





For any detectable single impurity:  
Not more than 0.1% 
Found:  
0.062 %<0.1 % 
Concerning the API 
Performed 
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CONCLUSION 
A rapid, economical, simple and sensitive HPLC method was 
developed and validated for the determination of enalapril maleate 
in tablet dosage form in presence of their impurities. The developed 
method can help research studies, quality control and routine 
analysis with lesser resources available. Therefore, the proposed 
validated method is fast and reliable and can be used for routine 
quantitative analysis as well as quality control of enalapril maleate 
in pharmaceutical formulation. 
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